The research focuses on the KCMF1/FUS/CENPT axis, a novel signaling pathway that has emerged from the study of tumor biology. The FUS protein, initially known for its role in RNA processing and regulation of gene expression, appears to have a multifaceted role in cancer biology, functioning beyond its traditional boundaries. In renal cell carcinoma, FUS has been shown to interact with other regulatory proteins, such as KCMF1 and CENPT, culminating in a cascade of biological events that may facilitate tumor growth and metastasis.

The study meticulously details how FUS operates within the KCMF1/FUS/CENPT axis to alter cellular behavior in RCC. The authors utilized cellular models to demonstrate that elevated levels of FUS expression correlate with aggressive features of renal tumors. This correlation underscores the potential of FUS as a therapeutic target. By inhibiting FUS activity, it may be possible to attenuate cancer cell proliferation and promote tumor cell death, presenting an innovative approach to RCC treatment.

Furthermore, the authors explored the JNK signaling pathway’s activation as a downstream effect of FUS involvement in RCC progression. The c-Jun N-terminal kinase (JNK) pathway is instrumental in regulating processes such as apoptosis and cellular growth. The researchers highlight that the interaction between FUS and JNK not only facilitates tumor survival but also enhances the inflammatory milieu of the tumor microenvironment, contributing to a more aggressive cancer phenotype. This dual role emphasizes JNK’s significance as a potential therapeutic target, working synergistically with strategies aimed at FUS inhibition.

The experimental setup included a series of in vitro assays and in vivo models to validate the findings. By employing specific inhibitors and gene knockdown techniques, the team was able to establish a clear causal relationship between FUS activity and RCC aggression. Their findings were consistent across multiple cell lines, demonstrating a robust effect that may translate across different RCC types. Such reproducibility is essential for clinical relevance and future therapeutic development.

The implications of this research extend beyond simple understanding; it proposes that targeting the KCMF1/FUS/CENPT axis may represent a transformative strategy in RCC management. As RCC is often diagnosed at an advanced stage and notoriously resistant to conventional treatments, identifying new molecular targets like FUS offers hope for more effective therapeutic options. The potential of developing drugs aimed at this pathway is significant, propelling the need for further investigation.

Notably, the study also reveals the potential for combination therapies that involve JNK inhibitors alongside FUS targeting. This synergistic approach may enhance treatment efficacy, a critical consideration in cancer therapy where resistance to single-agent treatments frequently emerges. The findings suggest a holistic view of RCC therapy, where targeting multiple pathways can disrupt the cancer’s ability to adapt and thrive in hostile environments.

In parallel, the research brings to light the need for personalized medicine approaches within RCC treatment paradigms. The varying expression levels of FUS across different patients could serve as biomarkers for prognosis and treatment responsiveness, thereby enabling tailored therapeutic strategies. This aligns with a growing trend in oncology that emphasizes the need for bespoke treatments that cater to individual patient profiles rather than a one-size-fits-all methodology.

Another compelling aspect of this research is its potential to reframe existing understanding of FUS in oncology. Traditionally viewed merely as an RNA-binding protein associated with certain malignancies, this study positions FUS as an integral player in RCC progression mechanisms. Such a shift in perception can inspire future studies to systematically investigate FUS’s role in other cancers, potentially leading to broad-spectrum cancer therapeutic strategies.

In essence, Jiang and colleagues’ work serves as a clarion call for the oncology community to invest in elucidating the complex pathways of cancer biology. The interconnectedness of molecular signaling pathways like that of KCMF1, FUS, and CENPT suggests a web of interactions that could be unraveled to reveal new targets for intervention. It invites further exploration and perhaps even the development of new investigative paradigms that focus on these intricate relationships.

As this science unfolds, the need for collaborative efforts spanning molecular biology, pharmacology, and clinical research becomes paramount. Researchers and clinicians alike must converge to expedite the translation of these findings into clinical practice, ensuring that emerging treatments based on the elucidated pathways can reach those in need efficiently. That task, while daunting, offers the potential reward of saving lives and improving outcomes for those afflicted by one of the most challenging forms of cancer.

The journey from bench to bedside is often fraught with obstacles, yet the urgency of this research provides impetus for ongoing studies. The collective mission may now include not just striving for scientific excellence but also fostering partnerships that bridge the gap between discovery and clinical application. In the fast-evolving world of cancer therapeutics, such initiatives are not only necessary but could be transformative in ensuring patient survival and improved quality of life.

In conclusion, the intricate relationship between FUS and renal cell carcinoma underscores a promising horizon for cancer research and treatment. The unveiling of the KCMF1/FUS/CENPT axis combined with the influence of JNK signaling represents a convergence of novel insights that may shift the paradigms of RCC therapy. The call to action is clear: harness these discoveries into practice, making strides towards a future where RCC can be effectively managed and possibly cured.

Subject of Research: Renal Cell Carcinoma Progression and the Role of FUS

Article Title: Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway.

Article References: Jiang, Z., Zhang, R., Qi, Y. et al. Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway. J Transl Med 23, 1207 (2025). https://doi.org/10.1186/s12967-025-07254-z

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07254-z

Keywords: Renal cell carcinoma, Fused in Sarcoma, KCMF1, JNK signaling pathway, cancer progression, molecular pathways, targeted therapy.

ER+ breast cancer represents approximately 70% of all breast cancer cases worldwide and is frequently managed with endocrine therapies that disrupt estrogen signaling, a major driver of tumor growth. Although these therapies have improved patient outcomes, a significant challenge remains: a substantial fraction of tumors develop resistance, leading to relapse and metastatic progression. The recent approval and use of CDK4/6 inhibitors in combination with endocrine therapy have further enhanced progression-free survival in high-risk patients. However, not all patients benefit, spotlighting an urgent need to understand the molecular basis of this resistance phenomenon.

At the heart of the team’s investigation is the JNK signaling pathway, a critical cellular mechanism generally understood as both a modulator of stress-induced apoptosis and a regulator of cell cycle arrest. This pathway functions akin to an intracellular alarm system, activated upon cellular stressors such as DNA damage, oxidative stress, or cytotoxic therapies. Activation of the JNK pathway promotes processes that either halt cell proliferation or induce programmed cell death, mechanisms crucial for eliminating damaged or potentially oncogenic cells.

The researchers, led by Associate Professor Liz Caldon and Dr. Sarah Alexandrou, employed an innovative genome-wide CRISPR-Cas9 screen to systematically inactivate every gene across the genome in cultured ER+ breast cancer cells. This approach enabled them to pinpoint which genes, when silenced, confer resistance to combined endocrine and CDK4/6 inhibitor therapies. Strikingly, they discovered that disruption of multiple components of the JNK pathway, particularly the upstream kinase MAP2K7, allowed cancer cells to ignore therapeutic stress signals, continuing unabated proliferation and survival despite treatment.

Further validation involved analysis of tumor biopsies obtained from 78 ER+ breast cancer patients. Tumors exhibiting diminished JNK pathway activity correlated strongly with inferior therapy response and worse clinical outcomes. These findings collectively suggest that impaired JNK signaling functions as a molecular shield, permitting cancer cells to evade the cytostatic and cytotoxic effects of endocrine agents and CDK4/6 inhibitors by effectively silencing the stress alarms that would otherwise trigger senescence or apoptosis.

The revelation that the JNK pathway can act as a tumor suppressor contrasts with its previously held reputation in some cancer contexts as primarily tumor-promoting, underscoring the complexity of signal transduction networks within different cellular milieus. Within ER+ breast cancer, the balanced activity of the JNK pathway appears imperative; both hyperactivation and loss can perturb homeostasis, but loss notably drives therapeutic resistance. This dualistic role highlights a critical nuance in the pathway’s biology that can inform future therapeutic strategies.

Beyond mechanistic insights, the study offers translational promise. By developing biomarkers to assess JNK pathway functionality, clinicians could stratify patients prior to therapy initiation, identifying those unlikely to benefit from standard endocrine and CDK4/6 inhibitor regimens. This stratification would pave the way for personalized medicine, steering resistant patients toward alternative or adjunctive treatments and thereby optimizing clinical outcomes while minimizing unnecessary toxicity.

The Garvan team is spearheading ongoing research to unearth alternative therapeutic options tailored to cancers with suppressed JNK signaling. These efforts include screening for drugs capable of reactivating the pathway or exploiting vulnerabilities engendered by its silencing. The ultimate goal is a paradigm in which a patient’s tumor signaling profile guides bespoke treatment algorithms, maximizing efficacy and extending survival.

Importantly, this research underscores the value of integrating sophisticated genetic screening tools like CRISPR with patient-derived data to unravel complex biological resistance mechanisms. By combining high-throughput functional genomics with clinical sample analysis, the study establishes a robust framework for future oncology research aimed at overcoming drug resistance.

The implications of these findings extend beyond ER+ breast cancer, suggesting that similar stress response pathways may govern therapeutic resistance in other malignancies. As drug resistance remains a pervasive barrier in oncology, insights from the JNK pathway and its regulatory networks open new frontiers for investigation across cancer types.

This work was made possible through funding from diverse sources, including the National Breast Cancer Foundation and philanthropic awards, highlighting the synergistic role of public and private support in advancing cancer research. The team also acknowledges the important contributions of consumer advocates, emphasizing patient involvement in shaping impactful research agendas.

The promise embodied by this study is profound: in the near future, assessing the activity of cellular stress pathways like JNK may become routine in clinical oncology, informing decisions that tailor treatments to the molecular fingerprints of each tumor. For patients battling ER+ breast cancer, such precision could redefine prognosis and transform therapeutic landscapes.

Subject of Research: People

Article Title: JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer

News Publication Date: 18-Aug-2025

Web References:
http://dx.doi.org/10.1186/s13046-025-03466-9

Image Credits: Garvan Institute

Keywords: Breast cancer, Drug resistance, Signal transduction, JNK pathway, Signaling pathways, Cancer treatments, Medical treatments, Cancer medication, Cancer, Estrogen receptors, Senescence